Singh P, et al. - Data were estimated to study the long-term efficacy of dulaglutide for management of diabetes mellitus in solid organ transplant (SOT) recipients. They noticed a statistically significant reduction in weight, body mass index (BMI) and insulin demand in 63 SOT recipients at 6, 12 and 24 months, respectively. They observed a mean paired difference for insulin reduction before and after dulaglutide treatment of 5.94 units. They noticed no incline in the risk of malignancy, cardiovascular morbidity, graft-failure or all-cause mortality. They found scarce gastrointestinal indications even in subjects with advanced chronic kidney disease (CKD) who required no adjustment in immunosuppressive agents.